Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: A focused update

Expert Opinion on Biological Therapy

Volumn 14, Issue 8, 2014, Pages 1121-1126

  Sellar, Rob S ^a   Peggs, Karl S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Allogeneic transplant; Cellular therapy; Cytomegalovirus; Immune response

Indexed keywords

BENZIMIDAVIR; BRINCIDOFOVIR; CIDOFOVIR; CYTOMEGALOVIRUS VACCINE; LETERMOVIR; ACETIC ACID DERIVATIVE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CYTOSINE; PHOSPHONIC ACID DERIVATIVE; QUINAZOLINE DERIVATIVE; RIBONUCLEOSIDE;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CELL THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; VACCINATION; VIRUS IMMUNITY; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; PROCEDURES; TRANSMISSION; TRANSPLANTATION;

ACETATES; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; ORGANOPHOSPHONATES; QUINAZOLINES; RIBONUCLEOSIDES; T-LYMPHOCYTES; TRANSPLANT RECIPIENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84904024988     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.908847     Document Type: Review

References (17)

1. Sellar RS, Peggs KS. Therapeutic strategies for the prevention and treatment of cytomegalovirus infection. Expert Opin Biol Ther 2012;12(9):1161-72
2. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, double-blind, placebocontrolled, randomised trial. Lancet Infect Dis 2011;11(4):284-92
3. Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, double-blind, multicenter controlled trial. Am J Transplant 2012;12(11):3021-30
4. Marty FM, Boeckh M. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr Opin Virol 2011;1(6):555-62
5. Alain S, Revest M, Veyer D, et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc 2013;45(4):1603-7
6. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010;12(6):489-96
7. Schubert A, Ehlert K, Schuler-Luettmann S, et al. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC Infect Dis 2013;13:330
8. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoieticcell transplantation. N Engl J Med 2013;369(13):1227-36
9. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011;11(5):1079-84
10. Blyth E, Clancy L, Simms R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMVdirected pharmacotherapy after allogeneic stem cell transplantation. Blood 2013;121(18):3745-58
11. Hanley P, Leen A, Gee AP, et al. Multi-virus-specific T-cell therapy for patients after hematopoietic stem cell and cord blood transplantation. Blood 2013;122(21):140
12. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013;121(26):5113-23
13. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007;110(4):1123-31 (Pubitemid 47281407)
14. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: A randomised, doubleblind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012;12(4):290-9
15. Genini E, Percivalle E, Sarasini A, et al. Serum antibody response to the gH/gL/ pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 2011;52(2):113-18
16. Lilleri D, Kabanova A, Lanzavecchia A, et al. Antibodies against neutralization epitopes of human cytomegalovirus gH/ gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 2012;32(6):1324-31
17. Lilleri D, Kabanova A, Revello MG, et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 2013;8(3):e59863.